docetaxel anhydrous has been researched along with aminoimidazole carboxamide in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (aminoimidazole carboxamide) | Trials (aminoimidazole carboxamide) | Recent Studies (post-2010) (aminoimidazole carboxamide) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,913 | 35 | 830 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, WC; Chiu, FY; Fang, SH; Hsieh, KL; Huang, KH; Huang, MY; Huang, SP; Li, CY; Lin, IL; Liu, PL; Su, CC; Yeh, HC | 1 |
1 other study(ies) available for docetaxel anhydrous and aminoimidazole carboxamide
| Article | Year |
|---|---|
AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases; Transforming Growth Factor beta | 2019 |